---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-082785"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:29:21.716464+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Corvus terminates ATM equity programs with Jefferies

## Summary
- Terminated 2020 Sales Agreement (up to $50M) and 2021 Sales Agreement (up to $40M) with Jefferies LLC effective March 28, 2023.
- Both at-the-market offering programs are no longer available for use.
- No reason for termination provided in the filing.

## SEC filing metadata
- accession: 0001193125-23-082785
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000119312523082785/0001193125-23-082785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000119312523082785/d483536d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-082785
- JSON: https://secwatch.observer/filing/0001193125-23-082785.json
- Plain text: https://secwatch.observer/filing/0001193125-23-082785.txt

## Key facts
- Material Agreements
  Corvus Pharmaceuticals, Inc. terminated Sales Agreements with Jefferies LLC valued at At-the-Market Offering Program with aggregate offering price up to $50.0 million (2020) and up to $4 (effective 2023-03-28).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: At-the-Market Offering Program with aggregate offering price up to $50.0 million (2020) and up to $4
  - Effective: 2023-03-28
  source text: On March 28, 2023, the Company terminated the Sales Agreements effective immediately. As a result, the At-the-Market Offering Programs under each of the 2020 Sales Agreement and 2021 Sales Agreement are no longer available for use.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000119312523082785/0001193125-23-082785-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.